digital health companies glp-1 programs Startups, big players ramp up focus on weight loss drug market GLP-1 Business Report for Healthtech

Using electronic health records of 113 million patients in the U.S., of whom more than 1.6 million had T2D and were treated with GLP-1 receptor agonists, insulins or metformin, the Ohio team found that GLP-1 receptor agonists were associated with significantly lower risk of several OACs versus insulin, but not metformin

Free Radic Biol Med (2009) 47(4):33343

In terms of lowering HbA1c, it proved to be more effective than exenatide twice daily, by 1.12% vs

Wilding, et

Multiple studies have documented that patients tend to regain a substantial portion of the weight lost once the medication is discontinued

American Journal of Clinical Nutrition, 103(3), 738746